- Email: [email protected]
4916072 Process for the formation of human-human hybridoma
PATENT ABSTRACTS
656
The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-I (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
4916070 FIBRIN-SPECIFIC ANTIBODIES AND METHOD OF SCREENING FOR THE ANTIBODIES Gary R Matsueda, Edgar Haber assigned to The General Hospital Corporation The invention relates to a method of screening for fibrin clot-specific monoclonal antibodies and to the monoclonal antibodies screened by this method. The invention also relates to immundiagnostic and immunotherapeutic applications of the screened fibrin clot-specific monoclonal antibodies.
Compositions for the treatment of AIDS and ARC having the following compound as an active ingredient: See Patent for Chemical Structure where RI is OH, monophosphate, diphosphate, or triphosphate; or a pharmacologically acceptable salt thereof. The primary advantage of this compound is its highly selective anti-retroviral activity, i.e., it significantly decreases viral replication as measured as reverse transcriptase activity while demonstrating orders of magnitude less cytotoxicity than other anti-viral compounds such as AZT. In a preferred embodiment, the compound is present in an amount sufficient to inhibit the HIV reverse transcriptase activity but not significantly inhibit human DNA polymerase activity. Also included within the scope of this invention are 3'-azido2',3'-dideoxyuridine mono-, di-, and triphosphate and compositions containing these compounds as the active agent.
4916213 4916072 PROCESS FOR THE FORMATION OF HUMAN-HUMAN HYBRIDOMA Kimiyosh Tsuji, Nobuna Ikewaki, Yokohama, Japan assigned to Idemitsu Kosan Co Ltd A human-human hybridoma is formed by subjecting a transformed human cell to a proliferaton inhibitory treatment and then fusing the thus-treated human cell with a human antibody producing cell. A desired clone may be selected from the resultant fused cells by using an anti-HLA antibody.
4916122 3'-AZIDO-2',3' DIDEOXYURIDINE ANTI-RETROVIRAL COMPOSITION Chung K Chu, Raymond F Schinazi assigned to University of Georgia Research Foundation lnc; Emory Universi
RIBOSOMAL INHIBITING PROTEIN-IMMUNOGLOBULIN CONJUGATES WITH SPECIFICITY FOR TUMOR CELL SURFACE ANTIGENS, AND MIXTURES THEREOF Patrick Scannon, Robert Baldwin, Vera Byers assigned to Xoma Corporation Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. Hydridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively.
656
The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-I (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
4916070 FIBRIN-SPECIFIC ANTIBODIES AND METHOD OF SCREENING FOR THE ANTIBODIES Gary R Matsueda, Edgar Haber assigned to The General Hospital Corporation The invention relates to a method of screening for fibrin clot-specific monoclonal antibodies and to the monoclonal antibodies screened by this method. The invention also relates to immundiagnostic and immunotherapeutic applications of the screened fibrin clot-specific monoclonal antibodies.
Compositions for the treatment of AIDS and ARC having the following compound as an active ingredient: See Patent for Chemical Structure where RI is OH, monophosphate, diphosphate, or triphosphate; or a pharmacologically acceptable salt thereof. The primary advantage of this compound is its highly selective anti-retroviral activity, i.e., it significantly decreases viral replication as measured as reverse transcriptase activity while demonstrating orders of magnitude less cytotoxicity than other anti-viral compounds such as AZT. In a preferred embodiment, the compound is present in an amount sufficient to inhibit the HIV reverse transcriptase activity but not significantly inhibit human DNA polymerase activity. Also included within the scope of this invention are 3'-azido2',3'-dideoxyuridine mono-, di-, and triphosphate and compositions containing these compounds as the active agent.
4916213 4916072 PROCESS FOR THE FORMATION OF HUMAN-HUMAN HYBRIDOMA Kimiyosh Tsuji, Nobuna Ikewaki, Yokohama, Japan assigned to Idemitsu Kosan Co Ltd A human-human hybridoma is formed by subjecting a transformed human cell to a proliferaton inhibitory treatment and then fusing the thus-treated human cell with a human antibody producing cell. A desired clone may be selected from the resultant fused cells by using an anti-HLA antibody.
4916122 3'-AZIDO-2',3' DIDEOXYURIDINE ANTI-RETROVIRAL COMPOSITION Chung K Chu, Raymond F Schinazi assigned to University of Georgia Research Foundation lnc; Emory Universi
RIBOSOMAL INHIBITING PROTEIN-IMMUNOGLOBULIN CONJUGATES WITH SPECIFICITY FOR TUMOR CELL SURFACE ANTIGENS, AND MIXTURES THEREOF Patrick Scannon, Robert Baldwin, Vera Byers assigned to Xoma Corporation Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. Hydridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively.